Prestige Wealth Management Group LLC Purchases 965 Shares of Tempus AI, Inc. (NASDAQ:TEM)

Prestige Wealth Management Group LLC increased its position in Tempus AI, Inc. (NASDAQ:TEM) by 910.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,071 shares of the company’s stock after purchasing an additional 965 shares during the quarter. Prestige Wealth Management Group LLC’s holdings in Tempus AI were worth $36,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. First Horizon Advisors Inc. bought a new position in Tempus AI in the third quarter worth $30,000. Farther Finance Advisors LLC purchased a new stake in shares of Tempus AI in the 4th quarter worth about $34,000. FNY Investment Advisers LLC bought a new position in shares of Tempus AI in the 4th quarter worth about $67,000. IFP Advisors Inc purchased a new position in Tempus AI during the 4th quarter valued at about $76,000. Finally, US Bancorp DE bought a new stake in Tempus AI during the fourth quarter worth about $80,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Stock Performance

Shares of NASDAQ:TEM opened at $58.57 on Wednesday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The business has a 50-day simple moving average of $57.42 and a two-hundred day simple moving average of $51.46. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TEM. Piper Sandler decreased their target price on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Needham & Company LLC raised their price objective on Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. TD Cowen reiterated a “buy” rating and set a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Morgan Stanley increased their target price on Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th. Finally, Wolfe Research lowered Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $61.18.

Insider Activity

In other Tempus AI news, major shareholder Bradley A. Keywell sold 170,720 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $35.45, for a total value of $6,052,024.00. Following the transaction, the insider now directly owns 15,993,729 shares of the company’s stock, valued at approximately $566,977,693.05. This trade represents a 1.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Nadja West sold 809 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $51.11, for a total transaction of $41,347.99. Following the sale, the director now directly owns 37,705 shares of the company’s stock, valued at $1,927,102.55. The trade was a 2.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,598,969 shares of company stock valued at $317,194,162 over the last three months.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.